CAMBRIDGE, Mass., January 22, 2024 – Casma Therapeutics, Inc., a biotechnology company engaging the autophagy/lysosomal system to provide innovative new medicines, today announced that Leon Murphy, Ph.D., Chief Scientific Officer, will present at the joint Keystone Meeting for Proximity Based Therapeutics and Targeted Protein Degradation in the section of “Emerging Proximity Biology for Target Degradation.” […] The post Casma Therapeutics to Present at the Joint Keystone Meeting for Proximity Based Therapeutics and Targeted Protein Degradation appeared first on Casma Therapeutics .